期刊文献+

化疗联合免疫细胞治疗在晚期卵巢癌治疗中的应用 被引量:2

下载PDF
导出
摘要 目的探讨化疗联合免疫细胞治疗在晚期卵巢癌治疗中的应用。方法选取晚期卵巢癌患者178例,随机数字法分为观察组和对照组,每组89例。对照组给予单纯化疗治疗,观察组给予化疗联合免疫细胞治疗,两组患者均治疗9周。对两组临床疗效、毒副作用发生情况、免疫功能改善及生存期进行观察。结果观察组治疗总有效率为61.80%,明显高于对照组的42.70%(P〈0.05);观察组肝功能损害发生率和骨髓抑制胃肠道反应发生率分别为10.1l%、8.99%,均显著低于对照组的23.60%、22.47%(P〈0.05);治疗后两组患者免疫功能均明显改善(P〈0.05),观察组免疫功能水平显著高于对照组(P〈0.05);观察组患者生存期为(41.32±2.52)个月,明显长于对照组的(29.42±2.57)个月(P〈0.05)。结论化疗联合免疫细胞治疗晚期卵巢癌疗效显著,毒副作用少,可有效提高患者免疫功能,延长患者生存期,值得推广与使用。
出处 《国际医药卫生导报》 2015年第15期2184-2186,共3页 International Medicine and Health Guidance News
  • 相关文献

参考文献6

二级参考文献62

  • 1Jiabo Di,Tjitske Duiveman-de Boer,Carl G Figdor,Ruurd Torensma.Aiming to immune elimination of ovarian cancer stem cells[J].World Journal of Stem Cells,2013,5(4):149-162. 被引量:7
  • 2Leffers N, Gooden MJ, deJong RA, et al. Prognostic significance oftumor--infiltrating T-lymphocytes in primary and metastatic le- sions of advanced stage ovarian cancer[J]. Cancer Immunol Immu- nother, 2009, 58(3):449-459.
  • 3Savage PA, Malchow S, Levendlal DS. Basic principles of tu- mor-associated regulatory T cell biology[J]. Trends Immunol, 2013, 34(1) :33-40.
  • 4Strauss L, Bergnann C, Gooding W, et al. The frequency and sup- pressor function of CD4+ CD25 high Foxp3+ T cells in the circula- tion of patients with squamous cell carcinoma of the head and neck [J]. Clin Cancer Res, 2007, 13(21):6301-6311.
  • 5Preston GC, Goode EL, Hartmann LC, et al. Immunity and im- mune suppression in human ovarian cancer[J]. Immunotherapy, 2011, 3(4): 539-556.
  • 6Tanaka H, Tanaka I, Kjaergaard I, et aI. Depletion of CD+CD25+ regulatory T cells augments the generation of specific immune T cella in tumor-draining lymph nodes[J].J Immunother, 2002, 25(3):207.
  • 7Dowlatshahi M, Huang V, Gehad AE, et al. Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses[J]. J Invest Der- matol, 2013, 133(7):1879-1889.
  • 8Gupta R, BabbJS, Singh B, et al. The numbers of FoxP3+ lympho- cytes in sentinel lymph nodes of breast cancer patients correlate with primary tumor size but not nodal stares[J]. Cancer Invest, 2011, 29(6):419-425.
  • 9Curiel TJ, Coukos G, Zou L, et al. Specific recruiunent of regulato- ry T cells in ovarian carcinoma fosters immune privilege and pre- dicts reduced surviva[J]. Nat Med, 2004, 10(9):942-949.
  • 10Sasada T, Kimura M, Yoshida Y, et al. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involve- ment of regulatory T cells in disease progression[J]. Cancer, 2003, 98 (5) : 1089-1 099.

共引文献82

同被引文献13

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部